EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Darifenacin: a promising chitinase 3-like 1 inhibitor to tackle drug resistance in pancreatic ductal adenocarcinoma

Sofia M Sousa, Helena Branco, Amir Avan, Andreia Palmeira, Luca Morelli, Lúcio L Santos, Elisa Giovannetti, M Helena Vasconcelos iD, Cristina P R Xavier iD

Cancer Chemotherapy and Pharmacology · 2024

DOI: 10.1007/s00280-024-04712-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2024. Verfasst von Sofia M Sousa und 8 weiteren Autor:innen. Beteiligte Einrichtung: i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen 208, Porto, 4200-135, Portugal. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Benzofurans, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidade do Porto.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Pancreatic ductal adenocarcinoma (PDAC) is among the most aggressive malignancies. Our previous work revealed Chitinase 3-like 1 (CHI3L1) involvement in PDAC resistance to gemcitabine, identifying it as a promising therapeutic target. Here, we aimed to identify putative CHI3L1 inhibitors and to investigate their chemosensitizing potential in PDAC.

Methods

Docking analysis for CHI3L1 identified promising CHI3L1 inhibitors, including darifenacin (muscarinic receptor antagonist). PDAC cell lines (BxPC-3, PANC-1) and primary PDAC cells were used to evaluate darifenacin’s effects on cell growth (Sulforhodamine B, SRB), alone or in combination with gemcitabine or gemcitabine plus paclitaxel. Cytotoxicity against normal immortalized pancreatic ductal cells (HPNE) was assessed. Recombinant protein was used to confirm the impact of darifenacin on CHI3L1-induced PDAC cellular resistance to therapy (SRB assay). Darifenacin’s effect on Akt activation was analysed by ELISA. The association between cholinergic receptor muscarinic 3 (CHRM3) expression and therapeutic response was evaluated by immunohistochemistry of paraffin-embedded tissues from surgical resections of a 68 patients’ cohort.

Results

In silico screening revealed the ability of darifenacin to target CHI3L1 with high efficiency. Darifenacin inhibited PDAC cell growth, with a GI 50 of 26 and 13.6 µM in BxPC-3 and PANC-1 cells, respectively. These results were confirmed in primary PDAC-3 cells, while darifenacin showed no cytotoxicity against HPNE cells. Importantly, darifenacin sensitized PDAC cells to standard chemotherapies, reverted CHI3L1-induced PDAC cellular resistance to therapy, and decreased Akt phosphorylation. Additionally, high CHMR3 expression was associated with low therapeutic response to gemcitabine.

Conclusion

This work highlights the potential of darifenacin as a chemosensitizer for PDAC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsBenzofuransDrug Resistance, NeoplasmPyrrolidinesReceptor, Muscarinic M3HumansCell Line, TumorGemcitabineCell ProliferationDeoxycytidineMolecular Docking SimulationProto-Oncogene Proteins c-aktChitinase-3-Like Protein 1

Stichwörter der Autor:innen

Cancer drug resistanceCancer treatmentChitinase-3 like 1DarifenacinMolecular dockingPancreatic cancer

Substanzen

darifenacinBenzofuransPyrrolidinesReceptor, Muscarinic M3CHI3L1 protein, humanCHRM3 protein, humanGemcitabineDeoxycytidineProto-Oncogene Proteins c-aktChitinase-3-Like Protein 1

Autor:innen und Institutionen

  • i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen 208, Porto, 4200-135, Portugal.
  • Cancer Drug Resistance Group, IPATIMUP - Institute of Molecular Pathology and Immunology, University of Porto, Rua Alfredo Allen 208, Porto, 4200-135, Portugal.
  • LQOF - Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira 228, Porto, 4050-313, Portugal.
  • Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, 91886-17871, Iran.
  • Medical Genetics Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, 91886-17871, Iran.
  • CIIMAR - Interdisciplinary Centre of Marine and Environmental Research, Terminal de Cruzeiros do Porto de Leixões, Matosinhos, 4450-208, Portugal.

ORCID-Profile: M Helena Vasconcelos, Cristina P R Xavier

Förderung

  • Universidade do Porto

Zitieren

APA

Sousa, S. M., Branco, H., Avan, A., Palmeira, A., Morelli, L., Santos, L. L., Giovannetti, E., Vasconcelos, M. H., & Xavier, C. P. R. (2024). Darifenacin: a promising chitinase 3-like 1 inhibitor to tackle drug resistance in pancreatic ductal adenocarcinoma. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-024-04712-1

Vancouver

Sousa SM, Branco H, Avan A, Palmeira A, Morelli L, Santos LL, et al. Darifenacin: a promising chitinase 3-like 1 inhibitor to tackle drug resistance in pancreatic ductal adenocarcinoma. Cancer Chemotherapy and Pharmacology. 2024. doi:10.1007/s00280-024-04712-1

BibTeX
@article{Sousa2024,
  author = {Sousa, Sofia M and Branco, Helena and Avan, Amir and Palmeira, Andreia and Morelli, Luca and Santos, Lúcio L and Giovannetti, Elisa and Vasconcelos, M Helena and Xavier, Cristina P R},
  title = {Darifenacin: a promising chitinase 3-like 1 inhibitor to tackle drug resistance in pancreatic ductal adenocarcinoma},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2024},
  doi = {10.1007/s00280-024-04712-1}
}
Kostenlos starten →